Erica B.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
- Safety and Efficacy of Asciminib, Blinatumomab, and Combination Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory BCR::ABL1+ or Ph-like ALL
- Phase 2/3 Randomized Open‑Label Study of MK‑1045 Versus Blinatumomab in Relapsed/Refractory CD19‑Positive B‑Cell Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 21 of 74 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in developing innovative therapeutic approaches for acute myeloid leukemia (AML), with particular focus on pediatric and young adult patients.
- Blood and Bone Marrow Malignancies
- Pediatric Leukemia Treatment
- Young Adult Cancer Care
The investigator's work encompasses advanced treatment strategies in cord blood transplantation and cellular therapies.
Immunotherapy Research
The investigator explores cutting-edge dendritic cell vaccination approaches in post-transplant settings, focusing on targeted immunological interventions.
- Cancer Vaccines
- Cellular Immunotherapy
- Post-Transplant Care
Their research integrates immune system modulation with conventional transplant procedures to enhance treatment outcomes.
Translational Medicine
The investigator's work bridges laboratory discoveries with clinical applications, particularly in targeted molecular therapies for hematologic cancers.
- Molecular Targeting
- Biomarker Research
- Treatment Optimization
Their research includes investigating survival outcomes and developing innovative therapeutic protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.